Sign in

    Arseniy Shabashvili

    Research Analyst at Guggenheim Securities

    Arseniy Shabashvili is an Associate and Equity Research Analyst at Guggenheim Securities, specializing in coverage of biotechnology and pharmaceutical companies such as Absci Corporation. He joined Guggenheim in 2022 following prior research roles at Mizuho and diverse industry experience including bioengineering leadership at Novartis and venture investments at RBV Capital. Shabashvili’s track record encompasses successful investment analysis and participation in profitable exits like the acquisition of Bonti for $300 million, supported by hands-on expertise in biomedical research. He holds credentials in finance and machine learning, with a strong background in life sciences that underpins his analytical approach.

    Arseniy Shabashvili's questions to Absci (ABSI) leadership

    Arseniy Shabashvili's questions to Absci (ABSI) leadership • Q2 2025

    Question

    Arseniy Shabashvili from Guggenheim Partners asked about the upcoming preclinical milestones for oncology programs ABS-301 and ABS-501, their path to IND-enabling studies, and the rationale for prioritizing the alopecia indication for ABS-201 over endometriosis.

    Answer

    CFO Zach Jonasson stated that the next step for the oncology programs is completing in vivo work for a development candidate package, after which they will be partnered. CEO Sean McClain added that Absci's internal focus is on I&I. Regarding ABS-201, McClain explained that the Phase 1/2a trial is designed to include female patients, preserving the option to pursue a Phase 2 trial in endometriosis in parallel to the alopecia program.

    Ask Fintool Equity Research AI

    Arseniy Shabashvili's questions to Absci (ABSI) leadership • Q2 2025

    Question

    Arseniy Shabashvili from Guggenheim Partners asked about the next preclinical milestones for oncology programs ABS-301 and ABS-501, and the company's latest thinking on prioritizing endometriosis for ABS-201.

    Answer

    CFO & CBO Zach Jonasson explained that the next step for the oncology programs is completing in vivo work for a development candidate package, after which they will be partnered. CEO Sean McClain added that for ABS-201, the Phase 1/2a trial will include female patients to preserve the option of pursuing an endometriosis indication in the future.

    Ask Fintool Equity Research AI

    Arseniy Shabashvili's questions to Absci (ABSI) leadership • Q1 2025

    Question

    Arseniy Shabashvili of Guggenheim Securities inquired about the expected outcomes for the ABS-101 Phase I trial data, specifically focusing on pharmacokinetics (PK) and immunogenicity, and asked about the potential for self-administration of ABS-201.

    Answer

    CEO Sean McClain and SVP of Drug Creation Christian Stegmann responded. For ABS-101, they are looking for a strong safety profile, low immunogenicity, and target engagement data similar to previous NHP studies. Stegmann added they aim to validate the extended half-life to support dosing every 8-12 weeks. Regarding ABS-201, McClain stated that while it could eventually be self-administered, the initial plan is to work with dermatologists.

    Ask Fintool Equity Research AI

    Arseniy Shabashvili's questions to Travere Therapeutics (TVTX) leadership

    Arseniy Shabashvili's questions to Travere Therapeutics (TVTX) leadership • Q2 2025

    Question

    Arseniy Shabashvili of Guggenheim Securities asked about the medical community's reception to new data from the SPARTAN studies and whether further real-world or biomarker data is anticipated to support Filspari's positioning as a disease-modifying therapy.

    Answer

    Dr. Jula Inrig, Chief Medical Officer, reported a very positive reception, with excitement around data showing Filspari's efficacy in combination with SGLT2 inhibitors and its effect on disease-modifying biomarkers. She confirmed plans to validate these findings using the large Phase 3 study biomarker set and present that data at future congresses.

    Ask Fintool Equity Research AI

    Arseniy Shabashvili's questions to Travere Therapeutics (TVTX) leadership • Q3 2024

    Question

    In a follow-up, Arseniy Shabashvili of Guggenheim Securities asked about FILSPARI's uptake among community-based nephrologists versus academic thought leaders, and whether the message is reaching a broader physician base post-full approval.

    Answer

    Chief Commercial Officer Peter Heerma responded that while it's still early post-full approval, the commercial strategy targets a broad base of ~6,000 nephrologists to reach the majority of patients, who reside in the community. He confirmed that prescription patterns show the majority of uptake is from community physicians, while also noting strong, positive feedback from academic leaders, especially with the support of the new KDIGO guidelines.

    Ask Fintool Equity Research AI